Summer 2026

Intern IT - Enterprise Architecture

Posted on 2/21/2026

Deadline 3/20/26
AskBio

AskBio

501-1,000 employees

Clinical-stage gene therapy company developing AAVs

No salary listed

Philadelphia, PA, USA + 1 more

More locations: Research Triangle, Durham, NC, USA

In Person

Category
Data & Analytics (1)
Required Skills
Sharepoint
Confluence
Information Architecture
Excel/Numbers/Sheets
Requirements
  • Must be pursuing a Bachelor’s degree in Information Systems, Computer Science, Data Analytics, Business Analytics, Management Information Systems (MIS) or related discipline
  • Must be at least a Junior at the time of application
  • Required Systems and Tool experience: Comfort navigating documentation repositories (SharePoint, Confluence, or similar); Ability to learn new internal systems (EA Repository/toolset, portfolio tools) with guidance; Experience organizing information in structured templates or spreadsheets
  • Required technical and analytical skills: Ability to work with Excel or Google Sheets to organize, filter, clean, and compare simple datasets; Coursework exposure to data models, databases, or information architecture concepts; Ability to understand and document metadata such as system names, owners, lifecycle stage, integration, and purpose; Familiarity with basic data quality concepts (completeness, consistency, duplication, accuracy)
  • Strong sense of accountability and ability to prioritize multiple tasks
  • Excellent organizational skills and meticulous attention to detail
  • Flexible and willing to support a variety of tasks for the IT team
  • Proactive, solution‑driven mindset with strong written and verbal communication skills
  • Available to work full‑time at the office during the summer months (May–August)
Responsibilities
  • Support updates to the Enterprise Architecture (EA) repository, focusing on improving accuracy, completeness, and consistency of application‑related data
  • Learn how EA data supports key IT functions including portfolio management, rationalization, capability mapping, integrations, and lifecycle planning
  • Review existing metadata and documentation for systems, applications, interfaces, owners, lifecycle stage, technical stacks, and business capabilities served
  • Partner with Application Owners, IT SMEs, and Business Partners to validate and correct EA repository entries
  • Observe how the EA repository is used for road mapping, budgeting, and strategic planning
  • Review application health, risk, and cost attributes (as provided) to ensure logical alignment across the portfolio
  • Participate in EA governance activities, including standardizing data definitions and improving intake/update processes
  • Assist in developing diagrams, portfolios, and dashboards derived from EA data
  • Maintain records of changes made in the EA repository and track open items requiring stakeholder follow‑up
  • Communicate findings clearly through summaries, visuals, and status updates
  • Collect insights and recommendations to support the creation of an EA Data Quality Playbook
  • Present a final intern presentation summarizing accomplishments, insights, and proposed next steps

AskBio focuses on developing adeno-associated virus (AAV) gene therapies for genetic and complex disorders. Therapies use AAV vectors to deliver therapeutic DNA into patients’ cells, advancing from research and preclinical work through clinical trials toward commercialization. Its differentiation comes from a clinical-stage portfolio, in-house R&D, and partnerships that emphasize collaboration and shared development. Its goal is to bring gene therapies to patients with unmet medical needs by validating therapies clinically and pursuing strategic collaborations for commercialization.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$4.2B

Headquarters

Durham, North Carolina

Founded

2001

Simplify Jobs

Simplify's Take

What believers are saying

  • AB-1009 began Phase 1/2 dosing on May 11, 2026 for late-onset Pompe.
  • AB-1005 and AB-1002 received Japan regenerative medicine designations in January 2026.
  • Fast Track and Orphan Drug designations support AB-1009 development and regulatory interaction.

What critics are saying

  • AB-1009 faces a tiny, open-label twelve-patient trial against entrenched ERT standards.
  • AB-1005 remains a sham-controlled neurosurgical Phase 2 gamble with brutal efficacy expectations.
  • Bayer can reprioritize spending, leaving AskBio underfunded despite its wholly owned structure.

What makes AskBio unique

  • AskBio started in 2001 advancing AAV technology for rare genetic disorders.
  • Bayer wholly owns AskBio, providing capital, infrastructure, and development scale.
  • AskBio has hundreds of proprietary third-generation gene vectors and multiple clinical programs.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at AskBio who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Performance Bonus

Profit Sharing

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Pet Insurance

Bereavement Leave

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Wellness Program

Mental Health Support

Gym Membership

Commuter Benefits

Meal Benefits

Phone/Internet Stipend

Home Office Stipend

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Pharma Press
Mar 25th, 2026
a-Klotho cell and gene therapy potential.

a-Klotho cell and gene therapy potential. 25 March 2026 Avaí Bio recently announced that it has initiated manufacturing of a master cell bank of genetically modified cells that overexpress the α-Klotho protein, working alongside joint venture partner Austrianova through their shared entity, Klothonova. A Master Cell Bank isn't a research milestone. It's a manufacturing milestone. It's the GMP-compliant, fully characterized starting material from which all working cell banks and final therapeutic products will be produced. It's the moment a cell therapy programme transitions from "we think this could work" to "we're building the production infrastructure to deliver it." There is a key 'master' protein in your body called α-Klotho. The scientific community has been quietly obsessed with it since a Japanese researcher named Makoto Kuro-O discovered in 1997 that mice without the Klotho gene aged rapidly and died young - and mice with extra Klotho lived 30% longer. Since then, the research has only gotten more compelling. Peer-reviewed studies have linked higher Klotho levels to reduced risk of Alzheimer's, certain cancers, cardiovascular disease, and kidney failure. Mayo Clinic research has connected declining Klotho to arterial stiffness and vascular calcification. And here's the part that makes this personal: natural α-Klotho levels drop by approximately 50% after age 40. The protein that protects your brain, your heart, and your kidneys starts disappearing right when you need it most. The question the biotech industry is now racing to answer is simple: can you put it back? The global cell therapy market has surpassed $8.2 billion in 2026. The broader cell and gene therapy sector is forecast to surge from $10.4 billion to more than $45 billion by 2035. And at the intersection of regenerative medicine and longevity science, a small biotechnology company just hit a manufacturing milestone that turns the Klotho thesis from laboratory theory into production reality. The Cell-in-a-Box(R) technology is the delivery mechanism that makes the whole approach viable. When you transplant therapeutic cells into a patient, the immune system typically destroys them within days. Austrianova's encapsulation technology protects the cells inside a porous capsule, allowing the cells to continuously produce and secrete the target protein - in this case, α-Klotho - while protecting the cells from immune rejection. It's backed by over 50 peer-reviewed publications and decades of development. Avaí Bio's dual-programme approach targets both the Klothonova anti-aging platform and the Insulinova diabetes program, each leveraging the same Cell-in-a-Box(R) encapsulation technology. The addressable markets are enormous: Alzheimer's disease alone is projected to reach $32.8 billion by 2033, cardiovascular disease remains the leading cause of death globally, and kidney disease affects 850 million people worldwide.

ChemXpert
Apr 3rd, 2025
Bayer Heralds Pipeline Progress, Blockbuster Launches and Advanced

Through AskBio, a wholly owned subsidiary of Bayer, it is developing a gene therapy as a potential new approach for treating congestive heart failure.

AskBio
Nov 5th, 2024
Brain Neurotherapy Bio | AskBio

Brain Neurotherapy Bio, Inc (BNB) is pleased to announce its recent merger with Asklepios BioPharmaceutical, Inc (AskBio), a Bayer company.

BambuUP
Sep 25th, 2024
Belief BioMed to Collaborate with AskBio to Explore the Potential of New Gene Therapies

Belief BioMed to collaborate with AskBio to explore the potential of new gene therapies.

The Business Journals
Apr 9th, 2024
AskBio co-founder Jude Samulski steps down, successor named

As it advances its pipeline of gene therapies, AskBio is planning to expand in the Triangle, essentially doubling its local footprint by acquiring space in Morrisville on Airport Road.

INACTIVE